6:00 PM
 | 
Feb 01, 2013
 |  BC Extra  |  Company News

FDA approves Ravicti

FDA approved an NDA for Ravicti glycerol phenylbutyrate from Hyperion Therapeutics Inc. (NASDAQ:HPTX) for the management of chronic urea cycle disorders in patients two years of...

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >